Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

An in vitro method of expanding T cells includes isolating T cells from a blood sample of a human subject, activating the isolated T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated T cells, and optionally restimulating the expanded T cells.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

The present invention provides a method of treating a cancer in a patient or subject in need thereof comprising administering a population of modified tumor infiltrating lymphocytes (TILs), wherein the population of TILs has been modified by adding an epigenetic reprogramming agent to the cell culture medium used for expanding the TILs.

Provided in the present invention are the preparation for a chimeric antigen receptor immune cell constructed on the basis of a growth arrest-specific protein 6 and the use of the chimeric antigen receptor immune cell. Specifically, provided in the present invention is a chimeric antigen receptor (CAR) based on GAS6 transformation. The CAR contains an extracellular binding domain, which can specifically target a GAS6 receptor. The CAR immune cell of the present invention has a strong specificity and target affinity, thereby also having a strong target cell killing capability and a high safety.

The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

Provided is a new therapeutic composition. A composition for treating a solid malignant tumor, the composition being used so as to be administered, in combination with at least one type selected from the group consisting of immature dendritic cells and cytotoxic lymphocytes induced by dendritic cells, to a subject having a malignant tumor cell that produces at least one type of inflammatory cytokine selected from the group consisting of TNF, IL-1, IL-5, IL-6, IL-8, IL-17, and IL-23, and the composition containing at least one type of antibody that inhibits action of the inflammatory cytokine.

Disclosed are methods of making engineered cells comprising reduced Sirt6 expression as well as the cells that are the products of said methods. Thus, in one aspect, disclosed herein are engineered lymphocytes comprising reduced Sirt6 expression. Also disclosed herein are methods of treating cancer in a subject that involves collecting lymphocytes, such as tumor infiltrating lymphocytes (TILs), from the subject, treating the lymphocytes ex vivo to inhibit Sirt6 expression, and transferring the modified lymphocytes to a subject with a cancer.

The present invention provides a method of treating a patient diagnosed with Myxoid/Round cell liposarcoma with an anti-GPC3 therapeutic agent. The present invention also relates to quantification of GPC3 expression in tissue samples of patients diagnosed with Myxoid/Round cell liposarcoma by an immunostaining assay and identification of GPC3 expression levels that correlate with selection of patients for administering the anti-GPC3 therapeutic agent.

The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.